vs

Side-by-side financial comparison of AMICUS THERAPEUTICS, INC. (FOLD) and Riley Exploration Permian, Inc. (REPX). Click either name above to swap in a different company.

AMICUS THERAPEUTICS, INC. is the larger business by last-quarter revenue ($185.2M vs $97.3M, roughly 1.9× Riley Exploration Permian, Inc.). On growth, AMICUS THERAPEUTICS, INC. posted the faster year-over-year revenue change (23.7% vs -5.3%). Over the past eight quarters, AMICUS THERAPEUTICS, INC.'s revenue compounded faster (29.5% CAGR vs -1.2%).

Amicus Therapeutics, Inc. is a public American biopharmaceutical company based in Philadelphia, Pennsylvania. The company went public in 2007 under the Nasdaq trading symbol FOLD. This followed a 2006 planned offering and subsequent withdrawal, which would have established the trading symbol as AMTX Prior to their IPO, Amicus was funded by a variety of venture capital firms including Radius Ventures, Canaan Partners and New Enterprise Associates.

Riley Exploration Permian, Inc. is an independent energy company focused on exploration, development, and production of crude oil, natural gas, and natural gas liquids primarily in the US Permian Basin spanning Texas and New Mexico. It prioritizes cost-efficient onshore reserve development to supply reliable energy products to North American markets.

FOLD vs REPX — Head-to-Head

Bigger by revenue
FOLD
FOLD
1.9× larger
FOLD
$185.2M
$97.3M
REPX
Growing faster (revenue YoY)
FOLD
FOLD
+29.0% gap
FOLD
23.7%
-5.3%
REPX
Faster 2-yr revenue CAGR
FOLD
FOLD
Annualised
FOLD
29.5%
-1.2%
REPX

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
FOLD
FOLD
REPX
REPX
Revenue
$185.2M
$97.3M
Net Profit
$1.7M
Gross Margin
85.7%
Operating Margin
8.6%
26.9%
Net Margin
0.9%
Revenue YoY
23.7%
-5.3%
Net Profit YoY
-88.5%
EPS (diluted)
$0.00
$4.02

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
FOLD
FOLD
REPX
REPX
Q4 25
$185.2M
$97.3M
Q3 25
$169.1M
$106.9M
Q2 25
$154.7M
$85.4M
Q1 25
$125.2M
$102.5M
Q4 24
$149.7M
$102.7M
Q3 24
$141.5M
$102.3M
Q2 24
$126.7M
$105.4M
Q1 24
$110.4M
$99.7M
Net Profit
FOLD
FOLD
REPX
REPX
Q4 25
$1.7M
Q3 25
$17.3M
$16.3M
Q2 25
$-24.4M
$30.5M
Q1 25
$-21.7M
$28.6M
Q4 24
$14.7M
Q3 24
$-6.7M
$25.7M
Q2 24
$-15.7M
$33.5M
Q1 24
$-48.4M
$18.8M
Gross Margin
FOLD
FOLD
REPX
REPX
Q4 25
85.7%
Q3 25
88.5%
Q2 25
90.2%
Q1 25
90.7%
Q4 24
90.1%
Q3 24
90.6%
Q2 24
91.1%
Q1 24
87.7%
Operating Margin
FOLD
FOLD
REPX
REPX
Q4 25
8.6%
26.9%
Q3 25
20.3%
27.0%
Q2 25
-6.1%
33.7%
Q1 25
-6.3%
48.3%
Q4 24
10.7%
31.2%
Q3 24
15.3%
17.1%
Q2 24
11.8%
50.9%
Q1 24
-25.1%
50.7%
Net Margin
FOLD
FOLD
REPX
REPX
Q4 25
0.9%
Q3 25
10.2%
15.3%
Q2 25
-15.8%
35.7%
Q1 25
-17.3%
27.9%
Q4 24
9.8%
Q3 24
-4.8%
25.1%
Q2 24
-12.4%
31.8%
Q1 24
-43.9%
18.8%
EPS (diluted)
FOLD
FOLD
REPX
REPX
Q4 25
$0.00
$4.02
Q3 25
$0.06
$0.77
Q2 25
$-0.08
$1.44
Q1 25
$-0.07
$1.36
Q4 24
$0.05
$0.52
Q3 24
$-0.02
$1.21
Q2 24
$-0.05
$1.59
Q1 24
$-0.16
$0.94

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
FOLD
FOLD
REPX
REPX
Cash + ST InvestmentsLiquidity on hand
$293.5M
Total DebtLower is stronger
$392.7M
$247.9M
Stockholders' EquityBook value
$274.2M
$634.2M
Total Assets
$949.9M
$1.2B
Debt / EquityLower = less leverage
1.43×
0.39×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
FOLD
FOLD
REPX
REPX
Q4 25
$293.5M
Q3 25
$263.8M
Q2 25
$231.0M
Q1 25
$250.6M
Q4 24
$249.9M
Q3 24
$249.8M
Q2 24
$260.1M
Q1 24
$239.6M
Total Debt
FOLD
FOLD
REPX
REPX
Q4 25
$392.7M
$247.9M
Q3 25
$392.0M
$367.0M
Q2 25
$391.3M
$275.2M
Q1 25
$390.7M
$249.3M
Q4 24
$390.1M
$269.5M
Q3 24
$389.5M
$288.6M
Q2 24
$388.9M
$322.7M
Q1 24
$388.4M
$341.8M
Stockholders' Equity
FOLD
FOLD
REPX
REPX
Q4 25
$274.2M
$634.2M
Q3 25
$230.4M
$566.5M
Q2 25
$204.3M
$556.9M
Q1 25
$193.6M
$532.4M
Q4 24
$194.0M
$510.6M
Q3 24
$178.8M
$507.4M
Q2 24
$132.5M
$489.0M
Q1 24
$130.7M
$434.6M
Total Assets
FOLD
FOLD
REPX
REPX
Q4 25
$949.9M
$1.2B
Q3 25
$868.8M
$1.2B
Q2 25
$815.3M
$1.0B
Q1 25
$789.8M
$994.9M
Q4 24
$785.0M
$993.5M
Q3 24
$786.6M
$997.9M
Q2 24
$749.5M
$1.0B
Q1 24
$721.8M
$956.4M
Debt / Equity
FOLD
FOLD
REPX
REPX
Q4 25
1.43×
0.39×
Q3 25
1.70×
0.65×
Q2 25
1.92×
0.49×
Q1 25
2.02×
0.47×
Q4 24
2.01×
0.53×
Q3 24
2.18×
0.57×
Q2 24
2.93×
0.66×
Q1 24
2.97×
0.79×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
FOLD
FOLD
REPX
REPX
Operating Cash FlowLast quarter
$16.3M
$64.9M
Free Cash FlowOCF − Capex
$16.0M
FCF MarginFCF / Revenue
8.6%
Capex IntensityCapex / Revenue
0.2%
Cash ConversionOCF / Net Profit
9.62×
TTM Free Cash FlowTrailing 4 quarters
$29.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
FOLD
FOLD
REPX
REPX
Q4 25
$16.3M
$64.9M
Q3 25
$35.7M
$63.6M
Q2 25
$-26.5M
$33.6M
Q1 25
$7.8M
$50.4M
Q4 24
$-3.9M
$66.4M
Q3 24
$-23.0M
$72.1M
Q2 24
$22.7M
$51.6M
Q1 24
$-29.7M
$56.1M
Free Cash Flow
FOLD
FOLD
REPX
REPX
Q4 25
$16.0M
Q3 25
$35.3M
Q2 25
$-28.9M
Q1 25
$7.5M
Q4 24
$-4.2M
Q3 24
$-23.3M
Q2 24
$21.6M
Q1 24
$-31.5M
FCF Margin
FOLD
FOLD
REPX
REPX
Q4 25
8.6%
Q3 25
20.9%
Q2 25
-18.7%
Q1 25
6.0%
Q4 24
-2.8%
Q3 24
-16.5%
Q2 24
17.0%
Q1 24
-28.5%
Capex Intensity
FOLD
FOLD
REPX
REPX
Q4 25
0.2%
Q3 25
0.2%
Q2 25
1.6%
Q1 25
0.2%
Q4 24
0.2%
Q3 24
0.3%
Q2 24
0.9%
Q1 24
1.6%
Cash Conversion
FOLD
FOLD
REPX
REPX
Q4 25
9.62×
Q3 25
2.06×
3.90×
Q2 25
1.10×
Q1 25
1.76×
Q4 24
-0.27×
Q3 24
2.81×
Q2 24
1.54×
Q1 24
2.99×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

FOLD
FOLD

Other$105.8M57%
Galafold$64.8M35%
Pombiliti Opfolda$14.6M8%

REPX
REPX

Segment breakdown not available.

Related Comparisons